Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2018-11-14 Capital/Financing Update
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
POST-EFFECTIVE AMENDMENT NO. 1 TO THIS REGISTRATION STATEMENT
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission. It is related to the registration of securities under the Securities Act of 1933, specifically for an initial public offering (IPO) of American Depositary Shares (ADSs) of Tiziana Life Sciences plc. The document includes detailed information typical of a registration statement such as underwriting details, risk factors, financial data presentation, and legal matters. This type of filing is a capital markets document related to the company's financing activities and securities registration, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-11-14 English
Regulatory Filings 2018
Regulatory Filings
2018-11-13 English
Regulatory Filings 2018
Regulatory Filings
2018-11-13 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from Tiziana Life Sciences plc to the SEC requesting acceleration of the effective date for a Registration Statement on Form F-1. It is a correspondence related to a regulatory filing process, specifically about the timing of the registration statement becoming effective. The document does not contain financial data, audit information, or report content itself, but is a procedural communication. The length is short (1702 characters), and it is clearly an official regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and correspondence that do not fit other specific categories.
2018-11-09 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 95% confidence The document is a letter from an underwriter representative to the SEC regarding a Registration Statement on Form F-1, requesting acceleration of the effective date. It references distribution of a Preliminary Prospectus and compliance with securities regulations. This is related to capital raising activities and the registration of securities. The content is an update on financing and regulatory compliance rather than a financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2018-11-09 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from Tiziana Life Sciences plc to the SEC requesting acceleration of the effective date for a Registration Statement on Form F-1. It references Rule 461 under the Securities Act of 1933 and discusses procedural matters related to the registration statement's effectiveness. The document is short (1692 characters) and does not contain any financial data, report content, or detailed disclosures. It is a regulatory procedural communication rather than a financial report or announcement of voting results, management changes, or capital updates. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2018-11-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.